Literature DB >> 24341367

Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: a randomized, comparative, prospective study.

D-Y Ko1, S-Y Jeon, K-H Kim, K-H Song.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) with methyl aminolevulinate (MAL) is effective for treating multiple actinic keratoses (AKs). Ablative fractional laser (FL) creates vertical channels that may facilitate MAL delivery and improve PDT response.
OBJECTIVE: To evaluate the efficacy of FL-assisted PDT (FL-PDT) in treating facial AKs in Korean patients.
METHODS: A prospective randomized non-blinded trial initially evaluated 271 facial AKs in 45 patients. All patients underwent one session of MAL-PDT using a red light-emitting diode lamp at 37 J/cm(2) , and 23 patients with 135 AK lesions were randomly assigned to pre-treatment with a 2940-nm ablative fractional erbium:Yag laser. Patients were followed up at 1, 2 and 4 weeks and every month until 6 and 12 months post-treatment. Response, adverse events, cosmetic outcome and patient satisfaction were documented. Finally, a total of 236 facial AKs in 40 patients were enrolled and analysed in this study.
RESULTS: FL-PDT was significantly more effective than MAL-PDT at treating all AK grades (86.9% vs. 61.2%; P < 0.001). The efficacy of FL-PDT was most pronounced in treating Olsen grade III AKs (69.4% vs. 32.5%; P = 0.001). FL-PDT also showed a lower lesion recurrence rate than MAL-PDT (9.7% vs. 26.6%; P = 0.004). Excellent or good cosmetic outcome was reported in >90% cases. Erythema and hyperpigmentation intensities were higher in the FL-PDT group (P > 0.05). Side-effects were more frequent in the FL-PDT group, but these were mild and well tolerated (P > 0.05).
CONCLUSION: FL-PDT is effective for treating AKs, especially moderate-to-thick lesions.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24341367     DOI: 10.1111/jdv.12334

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Molecular effects of fractional ablative erbium:YAG laser treatment with multiple stacked pulses on standardized human three-dimensional organotypic skin models.

Authors:  Laurenz Schmitt; P M Amann; Y Marquardt; R Heise; K Czaja; P A Gerber; T Steiner; F Hölzle; Jens Malte Baron
Journal:  Lasers Med Sci       Date:  2017-03-15       Impact factor: 3.161

Review 2.  Photodynamic therapy in dermatology beyond non-melanoma cancer: An update.

Authors:  Xiang Wen; Yong Li; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-06-21       Impact factor: 3.631

3.  Ablative Fractional Laser-assisted Low-irradiance Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients: A Prospective, Randomized, Intraindividual Controlled Trial.

Authors:  Anke S Lonsdorf; Aric Keller; Julia Hartmann; Alexander H Enk; Patrick Gholam
Journal:  Acta Derm Venereol       Date:  2022-04-13       Impact factor: 3.875

Review 4.  Photodynamic Therapy and Non-Melanoma Skin Cancer.

Authors:  Liezel L Griffin; John T Lear
Journal:  Cancers (Basel)       Date:  2016-10-22       Impact factor: 6.639

5.  Drug penetration enhancement techniques in ablative fractional laser assisted cutaneous delivery of indocyanine green.

Authors:  Arne A Meesters; Marilin J Nieboer; Mitra Almasian; Giota Georgiou; Menno A de Rie; Rudolf M Verdaasdonk; Albert Wolkerstorfer
Journal:  Lasers Surg Med       Date:  2019-03-25       Impact factor: 4.025

6.  Split-Sided Chest Study of Skin Rejuvenation Comparing Low-Energy, 1,927-nm Thulium Fractional Laser Treatment Prior to Photodynamic Therapy Versus Photodynamic Therapy Alone.

Authors:  Jennifer Croix; Shannon Burge; Jennifer Chwalek; Robyn Gmyrek; Anne Chapas
Journal:  Lasers Surg Med       Date:  2019-11-14       Impact factor: 4.025

Review 7.  Combination-Based Strategies for the Treatment of Actinic Keratoses with Photodynamic Therapy: An Evidence-Based Review.

Authors:  Stefano Piaserico; Roberto Mazzetto; Emma Sartor; Carlotta Bortoletti
Journal:  Pharmaceutics       Date:  2022-08-18       Impact factor: 6.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.